Work

Erratum to: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections

Year: 2020

Type: erratum

Abstract: J Antimicrob Chemother 2020; 75: 2384–93 In the original published version of this article there was an error in the section entitled ‘Novel β-lactamase inhibitors in combination with ceftibuten or cefpodoxime’. The sentence ‘VNRX7145 is another β-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, B and C enzymes.’ should have read ‘VNRX7145 is another β-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, C and D enzymes, but not Class B.’ This error has now been corrected in the online version of the article. The authors apologize for this error. This has now been corrected online.

Source: Journal of Antimicrobial Chemotherapy

DOI: 10.1093/jac/dkaa424

Authors: Adam G Stewart, Patrick N A Harris, Andrew Henderson, Mark A Schembri, David L Paterson

Language: English

Topic: Antibiotic Resistance in Bacteria

Subfield: Molecular Medicine

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4205957181

Cites:

Cited by: 1

Related to: 10